Part 8: Pediatric Advanced Life Support: 2025 American Heart Association and American Academy of Pediatrics Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Appendix 1. Writing Group Disclosures

Appendix 1. Writing Group Disclosures
Writing Group Member Employment Research Grant Other
Research
Support
Speakers' Bureau/
Honoraria
Expert
Witness
Ownership Interest Consultant/
Advisory Board
Other
Javier J. Lasa
Children's Health Systems of Texas, UT Southwestern Medical Center None None None None None None Edwards Life Sciences Corporation*
Alexis A. Topjian The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine NIH†; Marinus Pharmaceuticals† None None None None Elsevier,
Associate Editor,
Resuscitation†
None
Gurpreet S. Dhillon Lucile Packard Children's Hospital at Stanford Medical Center None AHA Young Investigator’s Seed Grant Award 2019* None None None None None
Jonathan P. Duff University of Alberta and Stollery Children's Hospital None None None None None None None
Jennifer Hayes Children’s Hospital Orange County None None ZOLL Medical * None None None None
Beena D. Kamath-Rayne American Academy of Pediatrics None None None None None Cerebral Palsy Alliance Research Foundation* Lurie Children's Hospital;
Children's Healthcare of Atlanta†
Arielle Levy University of Montreal None None None None None None None
Melissa Mahgoub American Heart Association None None None None None None None
Ryan W. Morgan The Children's Hospital of Philadelphia NIH† None None None None None None
Taylor McCormick Denver Health AHRQ† None None None None None None
Joan S. Roberts University of Washington PEDICA study*; SAMURAI study* None None None None None Seattle Children's Hospital†
Catherine E. Ross Boston Children’s Hospital NHLBI† None None None None None None
Stephen M. Schexnayder University of Arkansas/Arkansas Children's Hospital Pediatric Critical Care None None None Love & Kirschenbaum LLLC† None American Heart Association† None
Todd Sweberg Zucker School of Medicine None None None None None None Nonin Medical*;
Abbott Laboratories*
Santiago O. Valdés Texas Children's Hospital - Baylor College of Medicine Milestone Pharmaceuticals* None None None None None Abbott Laboratories*;
AltaThera
Pharmaceuticals*;
Medtronic*

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. Disclosures are reviewed and mitigated through a conflict-of-interest process that consists of reviewing pertinent information which is then used to decide what action is required to maintain content integrity. Disclosures may include salary, wages or other remuneration of any kind (including but not limited to consulting or advising fees, speaking fees, research funding, ownership interests, honoraria, participation in pension or benefit plans or programs or other perquisites, and reimbursement for travel, lodging, and meals) given for services rendered or other activities for which remuneration is received or expected, whether that compensation or other remuneration is paid directly to the individual or to the individual’s employer or another third party.

*Modest.

†Significant